Kivizyme may be available in the countries listed below.
Lysozyme hydrochloride (a derivative of Lysozyme) is reported as an ingredient of Kivizyme in the following countries:
International Drug Name Search
Tobramicina may be available in the countries listed below.
Tobramicina (DCIT) is known as Tobramycin in the US.
International Drug Name Search
Glossary
| DCIT | Denominazione Comune Italiana |
Mainheart may be available in the countries listed below.
Bisoprolol fumarate (a derivative of Bisoprolol) is reported as an ingredient of Mainheart in the following countries:
International Drug Name Search
Afusona may be available in the countries listed below.
Diflucortolone 21-valerate (a derivative of Diflucortolone) is reported as an ingredient of Afusona in the following countries:
International Drug Name Search
Pharmakod toux sèche may be available in the countries listed below.
Pholcodine is reported as an ingredient of Pharmakod toux sèche in the following countries:
International Drug Name Search
Borophen may be available in the countries listed below.
Clindamycin dihydrogen phosphate (a derivative of Clindamycin) is reported as an ingredient of Borophen in the following countries:
International Drug Name Search
Amfetamina may be available in the countries listed below.
Amfetamina (DCIT) is also known as Amfetamine (Rec.INN)
International Drug Name Search
Glossary
| DCIT | Denominazione Comune Italiana |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Pendium may be available in the countries listed below.
Buspirone hydrochloride (a derivative of Buspirone) is reported as an ingredient of Pendium in the following countries:
International Drug Name Search
Topiramat-Actavis may be available in the countries listed below.
Topiramate is reported as an ingredient of Topiramat-Actavis in the following countries:
International Drug Name Search
Tropicamide Faure may be available in the countries listed below.
Tropicamide is reported as an ingredient of Tropicamide Faure in the following countries:
International Drug Name Search
Alagra may be available in the countries listed below.
Fexofenadine hydrochloride (a derivative of Fexofenadine) is reported as an ingredient of Alagra in the following countries:
International Drug Name Search
Rizalt may be available in the countries listed below.
Rizatriptan is reported as an ingredient of Rizalt in the following countries:
International Drug Name Search
Rivastigmine Actavis 4.5 mg hard capsules
Each capsule contains rivastigmine hydrogen tartrate corresponding to rivastigmine 4.5 mg.
For a full list of excipients, see section 6.1.
Hard capsule (Capsule).
Off-white to slightly yellow powder in a hard capsule with red cap and red body, with white imprint "RIV 4.5mg" on body.
Symptomatic treatment of mild to moderately severe Alzheimer's dementia.
Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer's dementia or dementia associated with Parkinson's disease. Diagnosis should be made according to current guidelines. Therapy with rivastigmine should only be started if a caregiver is available who will regularly monitor intake of the medicinal product by the patient.
Rivastigmine should be administered twice a day, with morning and evening meals. The capsules should be swallowed whole.
Initial dose
1.5 mg twice a day.
Dose titration
The starting dose is 1.5 mg twice a day. If this dose is well tolerated after a minimum of two weeks of treatment, the dose may be increased to 3 mg twice a day. Subsequent increases to 4.5 mg and then 6 mg twice a day should also be based on good tolerability of the current dose and may be considered after a minimum of two weeks of treatment at that dose level.
If adverse reactions (e.g. nausea, vomiting, abdominal pain or loss of appetite), weight decrease or worsening of extrapyramidal symptoms (e.g. tremor) in patients with dementia associated with Parkinson's disease are observed during treatment, these may respond to omitting one or more doses. If adverse reactions persist, the daily dose should be temporarily reduced to the previous well-tolerated dose or the treatment may be discontinued.
Maintenance dose
The effective dose is 3 to 6 mg twice a day; to achieve maximum therapeutic benefit patients should be maintained on their highest well tolerated dose. The recommended maximum daily dose is 6 mg twice a day.
Maintenance treatment can be continued for as long as a therapeutic benefit for the patient exists. Therefore, the clinical benefit of rivastigmine should be reassessed on a regular basis, especially for patients treated at doses less than 3 mg twice a day. If after 3 months of maintenance dose treatment the patient's rate of decline in dementia symptoms is not altered favourably, the treatment should be discontinued. Discontinuation should also be considered when evidence of a therapeutic effect is no longer present.
Individual response to rivastigmine cannot be predicted. However, a greater treatment effect was seen in Parkinson's disease patients with moderate dementia. Similarly a larger effect was observed in Parkinson's disease patients with visual hallucinations (see section 5.1).
Treatment effect has not been studied in placebo-controlled trials beyond 6 months.
Re-initiation of therapy
If treatment is interrupted for more than several days, it should be re-initiated at 1.5 mg twice daily. Dose titration should then be carried out as described above.
Renal and hepatic impairment
Due to increased exposure in moderate renal and mild to moderate hepatic impairment, dosing recommendations to titrate according to individual tolerability should be closely followed (see section 5.2).
Patients with severe liver impairment have not been studied (see section 4.3).
Children
Rivastigmine is not recommended for use in children.
The use of this medicinal product is contraindicated in patients with
- hypersensitivity to the active substance, other carbamate derivatives or to any of the excipients used in the formulation,
- severe liver impairment, as it has not been studied in this population.
The incidence and severity of adverse reactions generally increase with higher doses. If treatment is interrupted for more than several days, it should be re-initiated at 1.5 mg twice daily to reduce the possibility of adverse reactions (e.g. vomiting).
Dose titration: Adverse reactions (e.g. hypertension and hallucinations in patients with Alzheimer's dementia and worsening of extrapyramidal symptoms, in particular tremor, in patients with dementia associated with Parkinson's disease) have been observed shortly after dose increase. They may respond to a dose reduction. In other cases, rivastigmine has been discontinued (see section 4.8).
Gastrointestinal disorders such as nausea and vomiting may occur particularly when initiating treatment and/or increasing the dose. These adverse reactions occur more commonly in women. Patients with Alzheimer's disease may lose weight. Cholinesterase inhibitors, including rivastigmine, have been associated with weight loss in these patients. During therapy patient's weight should be monitored.
In case of severe vomiting associated with rivastigmine treatment, appropriate dose adjustments as recommended in section 4.2 must be made. Some cases of severe vomiting were associated with oesophageal rupture (see section 4.8). Such events appeared to occur particularly after dose increments or high doses of rivastigmine.
Care must be taken when using rivastigmine in patients with sick sinus syndrome or conduction defects (sino-atrial block, atrio-ventricular block) (see section 4.8).
Rivastigmine may cause increased gastric acid secretions. Care should be exercised in treating patients with active gastric or duodenal ulcers or patients predisposed to these conditions.
Cholinesterase inhibitors should be prescribed with care to patients with a history of asthma or obstructive pulmonary disease.
Cholinomimetics may induce or exacerbate urinary obstruction and seizures. Caution is recommended in treating patients predisposed to such diseases.
The use of rivastigmine in patients with severe dementia of Alzheimer's disease or associated with Parkinson's disease, other types of dementia or other types of memory impairment (e.g. age-related cognitive decline) has not been investigated and therefore use in these patient populations is not recommended.
Like other cholinomimetics, rivastigmine may exacerbate or induce extrapyramidal symptoms. Worsening (including bradykinesia, dyskinesia, gait abnormality) and an increased incidence or severity of tremor have been observed in patients with dementia associated with Parkinson's disease (see section 4.8). These events led to the discontinuation of rivastigmine in some cases (e.g. discontinuations due to tremor 1.7% on rivastigmine vs. 0% on placebo). Clinical monitoring is recommended for these adverse reactions.
As a cholinesterase inhibitor, rivastigmine may exaggerate the effects of succinylcholine-type muscle relaxants during anaesthesia. Caution is recommended when selecting anaesthetic agents. Possible dose adjustments or temporarily stopping treatment can be considered if needed.
In view of its pharmacodynamic effects, rivastigmine should not be given concomitantly with other cholinomimetic substances and might interfere with the activity of anticholinergic medicinal products.
No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam or fluoxetine in studies in healthy volunteers. The increase in prothrombin time induced by warfarin is not affected by administration of rivastigmine. No untoward effects on cardiac conduction were observed following concomitant administration of digoxin and rivastigmine.
According to its metabolism, metabolic interactions with other medicinal products appear unlikely, although rivastigmine may inhibit the butyrylcholinesterase mediated metabolism of other substances.
For rivastigmine no clinical data on exposed pregnancies are available. No effects on fertility or embryofoetal development were observed in rats and rabbits, except at doses related to maternal toxicity. In peri/postnatal studies in rats, an increased gestation time was observed. Rivastigmine should not be used during pregnancy unless clearly necessary.
In animals, rivastigmine is excreted into milk. It is not known if rivastigmine is excreted into human milk. Therefore, women on rivastigmine should not breast-feed.
Alzheimer's disease may cause gradual impairment of driving performance or compromise the ability to use machinery. Furthermore, rivastigmine can induce dizziness and somnolence, mainly when initiating treatment or increasing the dose. As a consequence, rivastigmine has minor or moderate influence on the ability to drive and use machines. Therefore, the ability of patients with dementia on rivastigmine to continue driving or operating complex machines should be routinely evaluated by the treating physician.
The most commonly reported adverse reactions are gastrointestinal, including nausea (38%) and vomiting (23%), especially during titration. Female patients in clinical studies were found to be more susceptible than male patients to gastrointestinal adverse reactions and weight loss.
The following adverse reactions, listed below in Table 1, have been accumulated in patients with Alzheimer's dementia treated with rivastigmine.
Adverse reactions in Table 1 are listed according to MedDRA system organ class and frequency category. Frequency categories are defined using the following convention: very common (
Table 1
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
The following additional adverse reactions have been observed with rivastigmine transdermal patches: anxiety, delirium, pyrexia (common).
Table 2 shows the adverse reactions reported in patients with dementia associated with Parkinson's disease treated with rivastigmine.
Table 2
| |
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
Table 3 lists the number and percentage of patients from the specific 24-week clinical study conducted with rivastigmine in patients with dementia associated with Parkinson's disease with pre-defined adverse events that may reflect worsening of parkinsonian symptoms.
Table 3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Symptoms
Most cases of accidental overdose have not been associated with any clinical signs or symptoms and almost all of the patients concerned continued rivastigmine treatment. Where symptoms have occurred, they have included nausea, vomiting and diarrhoea, hypertension or hallucinations. Due to the known vagotonic effect of cholinesterase inhibitors on heart rate, bradycardia and/or syncope may also occur. Ingestion of 46 mg occurred in one case; following conservative management the patient fully recovered within 24 hours.
Treatment
As rivastigmine has a plasma half-life of about 1 hour and a duration of acetylcholinesterase inhibition of about 9 hours, it is recommended that in cases of asymptomatic overdose no further dose of rivastigmine should be administered for the next 24 hours. In overdose accompanied by severe nausea and vomiting, the use of antiemetics should be considered. Symptomatic treatment for other adverse reactions should be given as necessary.
In massive overdose, atropine can be used. An initial dose of 0.03 mg/kg intravenous atropine sulphate is recommended, with subsequent doses based on clinical response. Use of scopolamine as an antidote is not recommended.
Pharmacotherapeutic group: anticholinesterases, ATC code: N06DA03
Rivastigmine is an acetyl- and butyrylcholinesterase inhibitor of the carbamate type, thought to facilitate cholinergic neurotransmission by slowing the degradation of acetylcholine released by functionally intact cholinergic neurones. Thus, rivastigmine may have an ameliorative effect on cholinergic-mediated cognitive deficits in dementia associated with Alzheimer's disease and Parkinson's disease.
Rivastigmine interacts with its target enzymes by forming a covalently bound complex that temporarily inactivates the enzymes. In healthy young men, an oral 3 mg dose decreases acetylcholinesterase (AChE) activity in CSF by approximately 40% within the first 1.5 hours after administration. Activity of the enzyme returns to baseline levels about 9 hours after the maximum inhibitory effect has been achieved. In patients with Alzheimer's disease, inhibition of AChE in CSF by rivastigmine was dose-dependent up to 6 mg given twice daily, the highest dose tested. Inhibition of butyrylcholinesterase activity in CSF of 14 Alzheimer patients treated by rivastigmine was similar to that of AChE.
Clinical studies in Alzheimer's dementia
The efficacy of rivastigmine has been established through the use of three independent, domain specific, assessment tools which were assessed at periodic intervals during 6 month treatment periods. These include the ADAS-Cog (a performance based measure of cognition), the CIBIC-Plus (a comprehensive global assessment of the patient by the physician incorporating caregiver input), and the PDS (a caregiver-rated assessment of the activities of daily living including personal hygiene, feeding, dressing, household chores such as shopping, retention of ability to orient oneself to surroundings as well as involvement in activities relating to finances, etc.).
The patients studied had an MMSE (Mini-Mental State Examination) score of 10-24.
The results for clinically relevant responders pooled from two flexible dose studies out of the three pivotal 26-week multicentre studies in patients with mild-to-moderately severe Alzheimer's Dementia, are provided in Table 4 below. Clinically relevant improvement in these studies was defined a priori as at least 4-point improvement on the ADAS-Cog, improvement on the CIBIC-Plus, or at least a 10% improvement on the PDS.
In addition, a post-hoc definition of response is provided in the same table. The secondary definition of response required a 4-point or greater improvement on the ADAS-Cog, no worsening on the CIBIC-Plus, and no worsening on the PDS. The mean actual daily dose for responders in the 6-12 mg group, corresponding to this definition, was 9.3 mg. It is important to note that the scales used in this indication vary and direct comparisons of results for different therapeutic agents are not valid.
Table 4
|
| |||
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
*p<0.05, **p<0.01, ***p<0.001
Clinical studies in dementia associated with Parkinson's disease
The efficacy of rivastigmine in dementia associated with Parkinson's disease has been demonstrated in a 24-week multicentre, double-blind, placebo-controlled core study and its 24-week open-label extension phase. Patients involved in this study had an MMSE (Mini-Mental State Examination) score of 10-24. Efficacy has been established by the use of two independent scales which were assessed at regular intervals during a 6-month treatment period as shown in Table 5 below: the ADAS-Cog, a measure of cognition, and the global measure ADCS-CGIC (Alzheimer's Disease Cooperative Study-Clinician's Global Impression of Change).
Table 5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 Based on ANCOVA with treatment and country as factors and baseline ADAS-Cog as a covariate. A positive change indicates improvement.
2 Mean data shown for convenience, categorical analysis performed using van Elteren test
ITT: Intent-To-Treat; RDO: Retrieved Drop Outs; LOCF: Last Observation Carried Forward
Although a treatment effect was demonstrated in the overall study population, the data suggested that a larger treatment effect relative to placebo was seen in the subgroup of patients with moderate dementia associated with Parkinson's disease. Similarly a larger treatment effect was observed in those patients with visual hallucinations (see Table 6).
Table 6
|
|
|
|
|
|
Bomathal may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Thiopental Sodium is reported as an ingredient of Bomathal in the following countries:
International Drug Name Search
Biocadmio may be available in the countries listed below.
Cadmium Sulfide is reported as an ingredient of Biocadmio in the following countries:
International Drug Name Search
Carmozacine may be available in the countries listed below.
Camostat mesilate (a derivative of Camostat) is reported as an ingredient of Carmozacine in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
Tilmicosin is reported as an ingredient of Micotil in the following countries:
Tilmicosin phosphate (a derivative of Tilmicosin) is reported as an ingredient of Micotil in the following countries:
International Drug Name Search
Atropine Faure may be available in the countries listed below.
Atropine sulfate (a derivative of Atropine) is reported as an ingredient of Atropine Faure in the following countries:
International Drug Name Search
Rec.INN
0133242-30-5
C25-H39-N3-O8
509
ß-Adrenergic blocking agent
(-)-[(S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl p-[(S)-2-hydroxy-3-[[2-(4-morpholinecarboxamido)ethyl]amino]propoxy]hydrocinnamate (WHO)
(-)-2,2-dimethyl-1,3-dioxolan-4S-ylmethyl 3-[4-[3-[2-(morpholinocarbonylamino)ethylamino]-2S-hydroxypropoxy]phenyl]propionate
4-[(2S)-2-Hydroxy-3-[[2-[(4-morpholinylcarbonyl)amino]ethyl]amino]propoxy]benzene-propanoic acid [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl ester
International Drug Name Search
Glossary
| IS | Inofficial Synonym |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| WHO | World Health Organization |
Cusicrom may be available in the countries listed below.
Cromoglicic Acid disodium salt (a derivative of Cromoglicic Acid) is reported as an ingredient of Cusicrom in the following countries:
International Drug Name Search
Citrate de Betaine may be available in the countries listed below.
Betaine citrate (a derivative of Betaine) is reported as an ingredient of Citrate de Betaine in the following countries:
International Drug Name Search
Beta K may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Potassium Chloride is reported as an ingredient of Beta K in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
Clindamycin hydrochloride (a derivative of Clindamycin) is reported as an ingredient of Clintabs in the following countries:
International Drug Name Search
Terazosine EG may be available in the countries listed below.
Terazosin is reported as an ingredient of Terazosine EG in the following countries:
Terazosin hydrochloride (a derivative of Terazosin) is reported as an ingredient of Terazosine EG in the following countries:
International Drug Name Search
Calcium D3 beta may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Calcium Carbonate is reported as an ingredient of Calcium D3 beta in the following countries:
Colecalciferol is reported as an ingredient of Calcium D3 beta in the following countries:
International Drug Name Search
Ketamine Hydrochloride (BANM, USAN) is known as Ketamine in the US.
International Drug Name Search
Glossary
| BANM | British Approved Name (Modified) |
| USAN | United States Adopted Name |
Cinoxacina may be available in the countries listed below.
Cinoxacina (DCIT) is known as Cinoxacin in the US.
International Drug Name Search
Glossary
| DCIT | Denominazione Comune Italiana |
Irinotécan Hospira may be available in the countries listed below.
Irinotecan hydrochloride trihydrate (a derivative of Irinotecan) is reported as an ingredient of Irinotécan Hospira in the following countries:
International Drug Name Search
Anesject may be available in the countries listed below.
Ketamine hydrochloride (a derivative of Ketamine) is reported as an ingredient of Anesject in the following countries:
International Drug Name Search
Antispa may be available in the countries listed below.
Scopolamine butylbromide (a derivative of Scopolamine) is reported as an ingredient of Antispa in the following countries:
International Drug Name Search
In the US, Menest (esterified estrogens systemic) is a member of the drug class estrogens and is used to treat Atrophic Urethritis, Atrophic Vaginitis, Breast Cancer, Breast Cancer - Palliative, Hypoestrogenism, Oophorectomy, Osteoporosis, Postmenopausal Symptoms, Primary Ovarian Failure and Prostate Cancer.
US matches:
Estradiol is reported as an ingredient of Menest in the following countries:
International Drug Name Search
Magnesium + Vitamin E Ratiopharm may be available in the countries listed below.
Magnesium Oxide light (a derivative of Magnesium Oxide) is reported as an ingredient of Magnesium + Vitamin E Ratiopharm in the following countries:
Tocopherol, α- acetate (a derivative of Tocopherol, α-) is reported as an ingredient of Magnesium + Vitamin E Ratiopharm in the following countries:
International Drug Name Search
Glimépiride Winthrop may be available in the countries listed below.
Glimepiride is reported as an ingredient of Glimépiride Winthrop in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
Lasalocid is reported as an ingredient of Purina Sugar Mag Block in the following countries:
International Drug Name Search
Toccata may be available in the countries listed below.
Oxazolam is reported as an ingredient of Toccata in the following countries:
International Drug Name Search
Beplarid may be available in the countries listed below.
Beraprost sodium (a derivative of Beraprost) is reported as an ingredient of Beplarid in the following countries:
International Drug Name Search
Kafosed may be available in the countries listed below.
Dextromethorphan hydrobromide (a derivative of Dextromethorphan) is reported as an ingredient of Kafosed in the following countries:
International Drug Name Search
Milteforan may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Miltefosine is reported as an ingredient of Milteforan in the following countries:
International Drug Name Search
Gliboral may be available in the countries listed below.
Glibenclamide is reported as an ingredient of Gliboral in the following countries:
International Drug Name Search
Lostad may be available in the countries listed below.
Losartan potassium salt (a derivative of Losartan) is reported as an ingredient of Lostad in the following countries:
International Drug Name Search
Madonella may be available in the countries listed below.
Ethinylestradiol is reported as an ingredient of Madonella in the following countries:
Levonorgestrel is reported as an ingredient of Madonella in the following countries:
International Drug Name Search
Extranase may be available in the countries listed below.
Bromelains is reported as an ingredient of Extranase in the following countries:
International Drug Name Search
Fungium may be available in the countries listed below.
Ketoconazole is reported as an ingredient of Fungium in the following countries:
International Drug Name Search
Calcional may be available in the countries listed below.
Calcium Carbonate is reported as an ingredient of Calcional in the following countries:
International Drug Name Search
Carvedilol Adico may be available in the countries listed below.
Carvedilol is reported as an ingredient of Carvedilol Adico in the following countries:
International Drug Name Search
Morfozid may be available in the countries listed below.
Morinamide hydrochloride (a derivative of Morinamide) is reported as an ingredient of Morfozid in the following countries:
International Drug Name Search
Artril may be available in the countries listed below.
Glucosamine sulfate (a derivative of Glucosamine) is reported as an ingredient of Artril in the following countries:
Ibuprofen is reported as an ingredient of Artril in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
In the US, Lysine (lysine systemic) is a member of the drug class nutraceutical products and is used to treat Aphthous Ulcer, Herpes Simplex and Herpes Simplex - Suppression.
US matches:
Rec.INN
B05XB03
0000056-87-1
C6-H14-N2-O2
146
Amino acid
L-Lysine
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
| DCIT | Denominazione Comune Italiana |
| IS | Inofficial Synonym |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Cefadroxil MK may be available in the countries listed below.
Cefadroxil monohydrate (a derivative of Cefadroxil) is reported as an ingredient of Cefadroxil MK in the following countries:
International Drug Name Search
Firac may be available in the countries listed below.
Clonixin lysine salt (a derivative of Clonixin) is reported as an ingredient of Firac in the following countries:
International Drug Name Search
Movelium may be available in the countries listed below.
Domperidone is reported as an ingredient of Movelium in the following countries:
International Drug Name Search
Penticillin may be available in the countries listed below.
Piperacillin sodium salt (a derivative of Piperacillin) is reported as an ingredient of Penticillin in the following countries:
International Drug Name Search
In the US, Imiglucerase (imiglucerase systemic) is a member of the drug class lysosomal enzymes and is used to treat Gaucher Disease and Thrombocytopenia.
US matches:
Rec.INN
A16AB02
0154248-97-2
C2532-H3843-N671-O711-S16
55575
Enzyme, replacement therapy
495-L-Histidineglucosylceramidase (human placenta isoenzyme protein moiety)
International Drug Name Search
Glossary
| BAN | British Approved Name |
| DCF | Dénomination Commune Française |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
